An integrated approach to the treatment of allergic rhinitis

Abstract

Introduction. Аllergic rhinitis is characterized by IgE-mediated inflammation and widely distributed in both adult and pediatric populations. The contact between allergen and mucous membrane is followed by sneezing, rhinorrhea, nasal blockage. It may affect the quality of life and result in upper and lower airway diseases. The treatment aims to reduce or eliminate symptoms, prevent exacerbations and complications. The optimal treatment should maintain a habitual way of patient’s life. Intranasal corticosteroids in combination with selective antagonist of the leukotriene receptor drug – montelukast (Ektalust) have high efficiency and optimal dosing regimen.Aim. The study was to conduct a literature search for effectiveness of selective antagonist of the leukotriene receptor – montelukast (Ektalust) in treatment of allergic rhinitis.Materials and methods. The search was executed using RSCI and MEDLINE by keywords.Results and discussion. Patients with allergic rhinitis who received combination therapy with intranal glucocorticosteroids in combination with montelukast noted a better result in assessing the quality of life and reducing clinical manifestations, compared with patients who received monotherapy.Conclusions. Based on the available data it can be concluded that montelukast (Ektalust) in combination with intranasal corticosteroids may improve quality of life due to reduction of symptoms of allergic rhinitis, especially in conjunction with asthma.